X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
1. Ar C69931mx
2. Ar-c69931mx
3. Cangrelor Tetrasodium
4. Kengreal
5. N(6)-(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)-5'-adenylic Acid Monoanhydride With Dichloromethylenebis(phosphonic Acid)
1. 163706-06-7
2. Kengreal
3. Cangrelor Free Acid
4. Ar-c69931xx
5. Chembl334966
6. 6aq1y404u7
7. 163706-06-7 (free Acid)
8. (dichloro((((((2r,3s,4r,5r)-3,4-dihydroxy-5-(6-((2-(methylthio)ethyl)amino)-2-((3,3,3-trifluoropropyl)thio)-9h-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)methyl)phosphonic Acid
9. [dichloro-[[[(2r,3s,4r,5r)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic Acid
10. (dichloromethylene)diphosphonic N-(2-(methylsulfanyl)ethyl)-2-((3,3,3-trifluoropropyl)sulfanyl-5'-adenylic Monoanhydride
11. 5'-adenylicacid,n-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-,anhydridewithp,p'-(dichloromethylene)bis[phosphonicacid](1:1)
12. Cangrelor [usan:inn:ban]
13. Unii-6aq1y404u7
14. Arl69931
15. Cangrelor [inn]
16. Cangrelor [mi]
17. Cangrelor (usan/inn)
18. Cangrelor [usan]
19. Cangrelor [who-dd]
20. Gtpl1776
21. Schembl6113860
22. Cangrelor [orange Book]
23. Ammd00024
24. Arl 69931mx
25. Chebi:90841
26. Hsdb 8489
27. Dtxsid90167651
28. Ar-c-69931mx
29. Bdbm50118225
30. Mfcd09837758
31. Zinc85537017
32. Am85616
33. Db06441
34. Ncgc00480787-02
35. 5'-o-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]-n-[2-(methylsulfanyl)ethyl]-2-[(3,3,3-trifluoropropyl)sulfanyl]adenosine
36. Ac-28809
37. Hy-19638
38. Cs-0016143
39. D03359
40. Q3655338
41. 5'-adenylic Acid, N-(2-(methylthio)ethyl)-2-((3,3,3-trifluoropropyl)thio)-, Monoanhydride With (dichloromethylene)bis(phosphonic Acid)
42. 5'-adenylicacid, N-(2-(methylthio)ethyl)-2-((3,3,3-trifluoropropyl)thio)-, Monoanhydride With (dichloromethylene)bis(phosphonic Acid)
| Molecular Weight | 776.4 g/mol |
|---|---|
| Molecular Formula | C17H25Cl2F3N5O12P3S2 |
| XLogP3 | -1 |
| Hydrogen Bond Donor Count | 7 |
| Hydrogen Bond Acceptor Count | 21 |
| Rotatable Bond Count | 15 |
| Exact Mass | 774.9483145 g/mol |
| Monoisotopic Mass | 774.9483145 g/mol |
| Topological Polar Surface Area | 307 Ų |
| Heavy Atom Count | 44 |
| Formal Charge | 0 |
| Complexity | 1140 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists
National Library of Medicine's Medical Subject Headings. Cangrelor. Online file (MeSH, 2018). Available from, as of November 8, 2018: https://meshb.nlm.nih.gov/search
/CLINICAL TRIALS/ ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. The Web site is maintained by the National Library of Medicine (NLM) and the National Institutes of Health (NIH). Each ClinicalTrials.gov record presents summary information about a study protocol and includes the following: Disease or condition; Intervention (for example, the medical product, behavior, or procedure being studied); Title, description, and design of the study; Requirements for participation (eligibility criteria); Locations where the study is being conducted; Contact information for the study locations; and Links to relevant information on other health Web sites, such as NLM's MedlinePlus for patient health information and PubMed for citations and abstracts for scholarly articles in the field of medicine. Cangrelor is included in the database.
NIH/NLM; ClinicalTrials.Gov. Available from, as of November 8, 2018: https://clinicaltrials.gov/
Kengreal is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor. /Included in US product label/
NIH; DailyMed. Current Medication Information for Kengreal (Cangrelor Injection, Powder, Lyophilized, For Solution) (Updated: August 10, 2016). Available from, as of November 13, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88b434fa-8891-4fd5-9d86-7ea64667c08f
The most common adverse effect of cangrelor reported in clinical trials was bleeding. Cases of transient dyspnea were also reported during clinical trials.
American Society of Health-System Pharmacists; Drug Information 2018. Bethesda, MD. 2018, p. 1661
Hypersensitivity reactions (e.g., anaphylaxis, bronchospasm, angioedema, stridor) have been reported with cangrelor therapy.
American Society of Health-System Pharmacists; Drug Information 2018. Bethesda, MD. 2018, p. 1660
Like other antiplatelet agents, cangrelor increases the risk of bleeding, which may be serious. In the CHAMPION PHOENIX trial, bleeding events of all severities were somewhat more common with cangrelor than with clopidogrel. In clinical trials, bleeding events in patients receiving cangrelor were mild, generally consisting of hematoma, ecchymosis, and oozing at the puncture site. In the CHAMPION PHOENIX trial, the rate of severe bleeding (per the Global Use of Strategies to Open Occluded Coronary Arteries [GUSTO] criteria) was not substantially increased by cangrelor, although the rate of major bleeding according to more sensitive criteria (Acute Catheterization and Urgent Intervention Triage Strategy [ACUITY]) was substantially higher with cangrelor than with clopidogrel (4.3 versus 2.5%). The increase in major bleeding with the ACUITY criteria was attributable to a greater incidence of hematoma at the site of vascular access in patients receiving cangrelor.
American Society of Health-System Pharmacists; Drug Information 2018. Bethesda, MD. 2018, p. 1660
Cangrelor should not be used in patients with substantial active bleeding. The antiplatelet effects of cangrelor are negligible 1 hour after discontinuance of the infusion.
American Society of Health-System Pharmacists; Drug Information 2018. Bethesda, MD. 2018, p. 1660
For more Drug Warnings (Complete) data for Cangrelor (11 total), please visit the HSDB record page.
For use as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
FDA Label
Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.
Platelet Aggregation Inhibitors
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)
Purinergic P2Y Receptor Antagonists
Compounds that bind to and block the stimulation of PURINERGIC P2Y RECEPTORS. Included under this heading are antagonists for specific P2Y receptor subtypes. (See all compounds classified as Purinergic P2Y Receptor Antagonists.)
B01
B01AC25
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
B - Blood and blood forming organs
B01 - Antithrombotic agents
B01A - Antithrombotic agents
B01AC - Platelet aggregation inhibitors excl. heparin
B01AC25 - Cangrelor
Route of Elimination
Following IV administration of [3H] cangrelor, 58% of radioactivity was recovered in urine. The remaining 35% of radioactivity was in feces, presumably following biliary excretion.
Volume of Distribution
In a study in healthy volunteers administration at a dose of 30 mcg/kg bolus plus 4 mcg/kg/min showed a volume of distribution of 3.9 L.
Clearance
The mean clearance is about 43.2 L/h.
/MILK/ It is not known whether Kengreal is excreted in human milk.
NIH; DailyMed. Current Medication Information for Kengreal (Cangrelor Injection, Powder, Lyophilized, For Solution) (Updated: August 10, 2016). Available from, as of November 13, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88b434fa-8891-4fd5-9d86-7ea64667c08f
Following IV administration of 3(H) Kengreal 58% of radioactivity was recovered in urine. The remaining 35% of radioactivity was in feces, presumably following biliary excretion. The average elimination half-life of Kengreal is about 3-6 minutes.
NIH; DailyMed. Current Medication Information for Kengreal (Cangrelor Injection, Powder, Lyophilized, For Solution) (Updated: August 10, 2016). Available from, as of November 13, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88b434fa-8891-4fd5-9d86-7ea64667c08f
In a study in healthy volunteers, Kengreal administration at a dose of 30 ug/kg bolus plus 4 mcg/kg/min showed a volume of distribution of 3.9 L. Plasma protein binding of Kengreal is about 97-98%.
NIH; DailyMed. Current Medication Information for Kengreal (Cangrelor Injection, Powder, Lyophilized, For Solution) (Updated: August 10, 2016). Available from, as of November 13, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88b434fa-8891-4fd5-9d86-7ea64667c08f
Cangrelor is deactivated rapidly in the circulation by dephosphorylation to its primary metabolite, a nucleoside, which has negligible anti-platelet activity. Cangrelor's metabolism is independent of hepatic function and it does not interfere with other drugs metabolized by hepatic enzymes.
Kengreal is deactivated rapidly in the circulation by dephosphorylation to its primary metabolite, a nucleoside, which has negligible anti-platelet activity. Kengreal's metabolism is independent of hepatic function and it does not interfere with other drugs metabolized by hepatic enzymes.
NIH; DailyMed. Current Medication Information for Kengreal (Cangrelor Injection, Powder, Lyophilized, For Solution) (Updated: August 10, 2016). Available from, as of November 13, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88b434fa-8891-4fd5-9d86-7ea64667c08f
The average elimination half-life of cangrelor is about 3-6 minutes.
Following IV administration of 3(H) Kengreal, ... elimination half-life of Kengreal is about 3-6 minutes.
NIH; DailyMed. Current Medication Information for Kengreal (Cangrelor Injection, Powder, Lyophilized, For Solution) (Updated: August 10, 2016). Available from, as of November 13, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88b434fa-8891-4fd5-9d86-7ea64667c08f
Cangrelor is a selective, reversible, P2Y12 platelet receptor antagonist which inhibits ADP platelet aggregation. ADP is typically released by damaged blood vessels, red blood cells, and/or platelets due to agonists stimulating platelet activity. ADP binds to P2Y12 to stimulate and complete platelet aggregation by inhibiting adenylyl cyclase by a Gi protein, thus potentiating dense granule secretion and increasing coagulation activity. Cangrelor acts on the same target as oral irreversible inhibitors clopidogrel and ticlopidine and has a similar mechanism of action, but is reversible and provides a fast onset and offset of action.
Cangrelor is a direct P2Y12 platelet receptor inhibitor that blocks ADP-induced platelet activation and aggregation. Cangrelor binds selectively and reversibly to the P2Y12 receptor to prevent further signaling and platelet activation.
NIH; DailyMed. Current Medication Information for Kengreal (Cangrelor Injection, Powder, Lyophilized, For Solution) (Updated: August 10, 2016). Available from, as of November 13, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88b434fa-8891-4fd5-9d86-7ea64667c08f
Market Place
